

# VISOLYR

## AGENTIC ADAPTIVE INTELLIGENCE™

*Navigating moments that matter.*

Visolyr® transforms cardiometabolic care, helping clinicians detect early disease signs and act before complications occur. Our proactive insights promote healthier populations and empower health systems to provide cost-effective, compassionate care.

### Early Detection

Identify  
cardiometabolic  
risks sooner

### Proactive Insights

Actionable alerts for  
clinicians

### Improved Outcomes

Reduce  
complications and  
hospitalizations

### Cost-Effective Care

Support sustainable  
health systems



### VISION

A future in which every person receives care that is proactive, tailored, and effective

### MISSION

Reimagine healthcare by surfacing early signs of disease risk and providing actionable insights that clinicians can independently review and apply in care decisions

+1.703.861.9897

[www.visolyr.io](http://www.visolyr.io)

[info@visolyr.io](mailto:info@visolyr.io)

# Cardiometabolic Health Navigator



## Problem

Traditional Care Plans are static, educational documents that patients struggle to follow consistently. Clinicians lack real-time visibility into adherence, risk changes, and day-to-day patient behaviors, making proactive intervention difficult.

## Solution

Visolyr transforms Care Plans into an adaptive, personalized care companion that guides daily actions, goals, and progress tracking. A clinician-facing dashboard highlights blood pressure trends, gaps in adherence, and symptom changes, enabling timely decisions and targeted outreach.

## Capabilities and Features



Personalized daily actions, SMART goals, and biometric tracking improve adherence



Real-time visibility helps clinicians intervene earlier and more effectively



Adaptive, AI-generated care plans evolve with each patient's risk profile



Seamlessly integrates into clinical workflows



Demonstrates the power of Visolyr's Agentic Adaptive Intelligence™ to deliver dynamic, patient-specific care experiences

## Value Proposition & Benefits

### For Clinicians:

- Earlier detection of uncontrolled BP, missed meds, and emerging risk
- Reduced time spent piecing together fragmented data
- Clearer decision-making supported by real-time patient updates

### For Patients:

- Higher adherence through personalized, achievable daily actions
- Better understanding of what to do and why, reducing confusion
- More consistent self-management and confidence in care

### For Health Systems:

- Fewer downstream complications tied to hypertension and diabetes
- Reduced acute care utilization through earlier intervention
- Improved quality scores and value-based performance

# Patient Safety Intelligence



## Problem

Adverse event detection is manual, burdensome, and error-prone. Clinicians struggle to synthesize EMR data, medication history, and FAERS signals into clear, actionable insights. Reporting often lacks context and delays patient safety interventions.

## Solution

Visolyr combines graph-based inferencing with LLM reasoning to automatically detect adverse events, interpret clinical signals, and produce structured, MedWatch-ready reports enriched with confidence scoring and contextual insights.

## Capabilities and Features



Automated detection and report generation reduce burden and improve safety



Real-time FAERS integration enables rapid signal lookup and trend analysis



Supports chronic disease and pharmacovigilance analytics using correlated clinical, claims, and safety data



Produces explainable outputs clinicians can trust



Creates a flexible framework that extends to compliance, safety, and precision medicine use cases

## Value Proposition & Benefits

### For Clinicians:

- Dramatically reduced administrative burden of AE documentation
- Faster recognition of medication-related risks
- Clear, explainable summaries that support clinical judgment

### For Patients:

- Safer medication management with timely risk detection
- Reduced likelihood of preventable adverse drug reactions
- Better communication and understanding of medication risks

### For Health Systems:

- Stronger patient safety oversight and regulatory compliance
- Fewer adverse events leading to costly ED visits or readmissions
- Improved pharmacovigilance across populations and treatment



## Problem

Care teams face a fragmented view of patient health, struggling to identify and manage high-risk individuals effectively. Critical information is scattered across various systems like EMR, lab results, claims, and social determinants of health (SDoH) data. This disjointed approach hinders proactive intervention, complicates outreach prioritization, impedes addressing patient-specific barriers, and makes tracking care plans difficult. These challenges are particularly acute in rural and community clinics due to significant gaps in resource coordination.

## Solution

Visolyr provides a single, intelligent workspace for population health. It identifies high- and rising-risk patients by synthesizing diverse data sources, surfaces actionable next steps for care teams, and integrates social determinants and coverage navigation tools to streamline care coordination. This enables health systems to deliver targeted, efficient, and equitable care across their patient populations.

## Capabilities and Features



Unified filtering by clinic, payer, condition, or risk level provides granular insights into patient populations.



Actionable guidance for outreach, referral coordination, and barrier resolution streamlines care team workflows.



Integrated SDoH data highlights critical social barriers such as transportation, housing, or financial issues.



Real-world sample: 562 of 690 rural patients flagged as high or rising risk with automated next-step recommendations.



Safety Intelligence module auto-generates FDA-ready reports, enhancing regulatory compliance and patient safety.



Insurance verification and benefit summaries streamline navigation for both patients and providers.

## Value Proposition & Benefits

### For Clinicians:

- Immediate visibility into which patients need attention most, enabling proactive care.
- Streamlined outreach using prioritized task lists and intelligent recommendations.
- Reduced workload by automating manual chart review and risk identification processes.

### For Patients:

- More timely follow-ups and outreach from care teams, improving engagement.
- Greater access to essential transportation, financial, or social support resources.
- Higher referral completion rates and improved continuity of care.

### For Health Systems:

- Stronger performance in chronic care management and population health metrics.
- Reduced no-shows, fewer care gaps, and better management of high-risk cases.
- Improved operational efficiency by focusing resources on the highest-risk groups.

# AI Image Analysis for Diabetic Retinopathy



## Problem

Early diabetic eye disease can go undetected due to limited specialist access, variability in screening quality, and lack of explainable diagnostic support that both clinicians and patients can easily understand.

## Solution

Visolyr's DR module uses deep learning, Grad-CAM explainability, and generative AI to classify retinal fundus images, highlight affected regions, and generate structured clinical and patient-friendly narratives.

## Capabilities and Features



Early detection support with interpretable heatmaps and structured findings



Built on NVIDIA Clara multimodal medical imaging tools



Provides differential context, urgency scoring, and care pathway recommendations



Generates plain-language and clinician-ready summaries to improve communication



Demonstrates how agent-driven, explainable AI enhances proactive and personalized eye care

## Value Proposition & Benefits

### For Clinicians:

- Faster screening with clear visual explanations
- Higher confidence in identifying early disease or ruling it out
- Consistent, reliable support when specialist access is limited

### For Patients:

- Earlier identification of eye disease before symptoms progress
- Easy-to-understand summaries that improve follow-through
- Reduced anxiety through clear explanations and next steps

### For Health Systems:

- Lower preventable vision-loss events and associated long-term costs
- Increased screening compliance, especially in primary care settings
- Ability to expand eye screening without requiring more specialists

+1.703.861.9897

[www.visolyr.io](http://www.visolyr.io)

[info@visolyr.io](mailto:info@visolyr.io)

## Problem

Metabolic dysfunction–associated steatotic liver disease (MASLD) impacts over a third of adults but is critically underdiagnosed in early stages. Clinicians face fragmented patient data, struggling to consolidate liver function tests, metabolic risk factors, and coded conditions for fibrosis risk assessment. Inconsistent FIB-4 calculations, scattered imaging results, and buried risk signals across EMR entries lead to patients progressing to advanced fibrosis unnoticed, resulting in avoidable complications and significantly higher healthcare costs.

## Solution

Visolyr's MASLD Screening Agent revolutionizes early detection by automating EMR data analysis. It normalizes diagnoses via UMLS, calculates real-time FIB-4 scores, and generates evidence-based recommendations. This provides clinicians with a unified view of patient liver health, metabolic risk, and fibrosis severity, enabling earlier intervention, improved outcomes, and reduced healthcare burden.

## Capabilities and Features



Automated FIB-4 Calculation using age, AST, ALT, and platelets drawn directly from EMR labs.



UMLS-powered diagnosis normalization to identify MASLD-relevant conditions across ICD-10 and SNOMED codes.



Detection of key metabolic drivers, including type 2 diabetes, obesity, dyslipidemia, and hypertension.



AI-generated clinical reasoning providing concise summaries of risks, care gaps, and recommended next steps.



Second-line test guidance (VCTE/FibroScan, ELF) based on personalized risk category.



Clear risk stratification (low, indeterminate, high fibrosis risk) aligned with current clinical guidelines.

## Value Proposition & Benefits

### For Clinicians:

- Earlier and more reliable identification of MASLD and high-risk fibrosis.
- Automated extraction of labs, conditions, and risk factors significantly reduces manual chart review time.
- Clear, guideline-consistent next-step guidance aligned with AASLD and AACE recommendations.
- Improved confidence in managing diagnostic uncertainty, especially for indeterminate FIB-4 cases.

### For Patients:

- Better understanding of their liver health and associated metabolic risks.
- More timely evaluation and prevention of fibrosis progression, leading to better long-term outcomes.
- Clearer follow-up instructions, improving adherence to necessary labs, imaging, and lifestyle recommendations.
- Reduced fear and confusion through simplified, actionable explanations of their condition and treatment plan.

### For Health Systems:

- Reduced downstream costs by enabling earlier detection and management of liver fibrosis.
- Fewer cirrhosis-related hospital admissions and emergency department visits.
- Stronger performance in value-based contracts tied to chronic disease management metrics.
- Scalable approach to risk stratification across large populations with minimal additional clinician burden.